The prevalence of pre-procedural kidney failure in patients undergoing transcatheter aortic valve replacement (TAVR) can be as high as 50 – 60% (stage 3 kidney failure or worse); it has been strongly associated with acute kidney deterioration and, ultimately, an increase of post TAVR mortality. A recent meta-analyzis of several small studies carried out in a single…
Bleeding and Mortality in Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) is much less invasive than surgical replacement. This is associated with a substantial reduction in bleeding events (up to 60% less). However, clinically relevant bleeding is still present in one every four patients who undergo TAVR, which is associated with morbidity and mortality. Cases of bleeding are not uniform: they may…
How to standardize frailty in aortic stenosis patients
Frailty is the patient’s diminished capacity to recover after pathological or iatrogenic processes. It has a fundamental role when considering valve replacement, be it surgical (SAVR) or transcatheter (TAVR). This was clearly observed in the PARTNER I and Core-Valve Pivotal trials, which showed that despite a 95% technical success, 2 in 5 patients showed poor quality…
Incomplete Revascularization Is Associated with Mortality in TAVR
Courtesy of Dr. Carlos Fava. TAVR has proven to be beneficial for inoperable and high-risk patients, as well as for intermediate-risk patients. However, while many comorbidities have been analyzed, the presence, severity, and impact of coronary disease has not been well studied yet. This study analyzed 1270 patients who underwent TAVR. They presented >50% lesions in a major epicardial…
Valve Deterioration after TAVI Is Rare and Should Not Prevent Advancement to Younger Populations
Durability ─or better yet, lack of deterioration─ is still a matter of debate when considering transcatheter aortic valve intervention (TAVI), especially now that it is being explored as a real alternative for younger patients. A recently published meta-analysis offers more evidence and suggests TAVI deterioration is mostly rare within the first 5 years. According to…
SOLACI CACI 2017 | When is the optimal timing for PCI: before or during TAVI
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Conrad Simpfendorfer, entitled “When is the optimal timing for PCI: before or during TAVI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | TAVI intermediate risk: Reality or passion?
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Flavio Ribichini, entitled “TAVI intermediate risk: Reality or passion?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Prevention of valvular thrombosis: antiaggregation or anticoagulation?
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Fernando Pineda, entitled “Prevention of valvular thrombosis: antiaggregation or anticoagulation?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | How to do a MitraClip simple and fast
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Saibal Kar, entitled “How to do a MitraClip simple and fast”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | TAVI: Clinical Evidence of long term durability of prosthetic valves
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dra. Carla Agatiello, entitled “TAVI: Clinical Evidence of long term durability of prosthetic valves”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Clinical evidence of TAVR in intermediate risk patients: Lessons from clinical trials
Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Andreas Baumbach, entitled “Clinical evidence of TAVR in intermediate risk patients: Lessons from clinical trials”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.